316 related articles for article (PubMed ID: 37345145)
21. Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives.
Jenke R; Reßing N; Hansen FK; Aigner A; Büch T
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562653
[TBL] [Abstract][Full Text] [Related]
22. Mass spectrometry and DigiWest technology emphasize protein acetylation profile from Quisinostat-treated HuT78 CTCL cell line.
Méhul B; Perrin A; Grisendi K; Galindo AN; Dayon L; Ménigot C; Rival Y; Voegel JJ
J Proteomics; 2018 Sep; 187():126-143. PubMed ID: 30012418
[TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
[TBL] [Abstract][Full Text] [Related]
24. The emerging roles of HDACs and their therapeutic implications in cancer.
Hai R; Yang D; Zheng F; Wang W; Han X; Bode AM; Luo X
Eur J Pharmacol; 2022 Sep; 931():175216. PubMed ID: 35988787
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of HDACs--effective drugs against cancer?
Müller S; Krämer OH
Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
[TBL] [Abstract][Full Text] [Related]
26. A novel epigenetic drug conjugating flavonoid and HDAC inhibitor confer suppression of acute myeloid leukemogenesis.
Zhang J; Gao X; Wei M; Li Y; Yang G; Yang C; Yu L
Clin Sci (Lond); 2021 Jul; 135(14):1751-1765. PubMed ID: 34282832
[TBL] [Abstract][Full Text] [Related]
27. Role of HDACs in normal and malignant hematopoiesis.
Wang P; Wang Z; Liu J
Mol Cancer; 2020 Jan; 19(1):5. PubMed ID: 31910827
[TBL] [Abstract][Full Text] [Related]
28. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
29. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
[TBL] [Abstract][Full Text] [Related]
30. Blockade of histone deacetylase inhibitor-induced RelA/p65 acetylation and NF-kappaB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 activation.
Dai Y; Rahmani M; Dent P; Grant S
Mol Cell Biol; 2005 Jul; 25(13):5429-44. PubMed ID: 15964800
[TBL] [Abstract][Full Text] [Related]
31. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
32. Development of an Efficient Screening System for HDAC Inhibitor Based on TCF Response Element.
Pang C; Dai L; He G; Lu Y; Zhang B
Anticancer Agents Med Chem; 2018; 18(15):2131-2136. PubMed ID: 30378504
[TBL] [Abstract][Full Text] [Related]
33. Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy.
Verza FA; Das U; Fachin AL; Dimmock JR; Marins M
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32585896
[TBL] [Abstract][Full Text] [Related]
34. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
35. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
[TBL] [Abstract][Full Text] [Related]
36. Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies.
Imai Y; Maru Y; Tanaka J
Cancer Sci; 2016 Nov; 107(11):1543-1549. PubMed ID: 27554046
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the Expression and Role of Histone Acetylation and Deacetylation in Dental Pulp Cells.
Yamauchi Y; Duncan HF
Methods Mol Biol; 2023; 2588():279-293. PubMed ID: 36418694
[TBL] [Abstract][Full Text] [Related]
38. Histone Deacetylases Inhibitors in the Treatment of Retinal Degenerative Diseases: Overview and Perspectives.
Zhang H; Dai X; Qi Y; He Y; Du W; Pang JJ
J Ophthalmol; 2015; 2015():250812. PubMed ID: 26137316
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE
Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
